Novo Nordisk and Vivtex Corporation have announced a partnership to develop oral biologic medicines for obesity, diabetes and associated comorbidities. Under the agreement, Vivtex will license select oral drug-delivery technologies to Novo Nordisk, while Vivtex is eligible to receive upfront payments totalling up to $2.1 billion, and tiered royalties on future product sales. “Novo Nordisk […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!